ZELTIQ Aesthetics, Inc. to Present at the Canaccord Genuity 36th Annual Growth Conference
/EINPresswire.com/ -- PLEASANTON, CA--(Marketwired - August 05, 2016) - ZELTIQ® (NASDAQ: ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced that Taylor Harris, Senior Vice President and Chief Financial Officer, is scheduled to present at the Canaccord Genuity 36
Event: Canaccord Genuity 36th Annual Growth Conference
Date: Thursday, August 11, 2016
Time: 11:00 am ET / 8:00 am PT
Participant: Taylor Harris, Senior Vice President and Chief
Financial Officer
Audio webcast of the Company's presentation will be available by visiting the investor relations section of ZELTIQ's web site at www.coolsculpting.com. A replay of the presentation will be available for 90 days.
About ZELTIQ® Aesthetics
ZELTIQ Aesthetics, Inc. is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. ZELTIQ's first commercial product, the CoolSculpting system, is designed to selectively reduce unwanted fat that may not respond to diet or exercise. The CoolSculpting procedure is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. It utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis. ZELTIQ developed the CoolSculpting procedure to safely, noticeably, and measurably reduce the fat layer.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
